Walleye Capital LLC Acquires New Shares in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Walleye Capital LLC has made a new investment of approximately $180,000 in Eyepoint Pharmaceuticals, acquiring 33,206 shares of the company.
• Eyepoint Pharmaceuticals has seen significant changes in institutional ownership, with multiple hedge funds increasing their stakes, resulting in over 99.41% of the company's stock being held by institutional investors.
• The company recently reported earnings of ($0.85) per share, missing analyst estimates, and has an average target price of $26.86 from analysts, indicating a consensus "Buy" rating.

Walleye Capital LLC acquired a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 33,206 shares of the company's stock, valued at approximately $180,000.

Other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Eyepoint Pharmaceuticals by 28.8% in the 4th quarter. Bank of America Corp DE now owns 648,030 shares of the company's stock worth $4,828,000 after buying an additional 145,065 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Eyepoint Pharmaceuticals by 70.7% in the 4th quarter. ProShare Advisors LLC now owns 21,679 shares of the company's stock worth $162,000 after buying an additional 8,981 shares during the last quarter. Millennium Management LLC acquired a new stake in Eyepoint Pharmaceuticals in the 4th quarter worth about $3,324,000. California State Teachers Retirement System boosted its holdings in Eyepoint Pharmaceuticals by 3.8% in the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after buying an additional 1,797 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Eyepoint Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock worth $20,782,000 after buying an additional 31,141 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EYPT has been the topic of several research analyst reports. Royal Bank Of Canada initiated coverage on Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 price objective on the stock. Chardan Capital restated a "buy" rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. HC Wainwright boosted their target price on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Finally, Mizuho lowered their target price on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $26.86.

Eyepoint Pharmaceuticals Stock Down 4.5%

Shares of Eyepoint Pharmaceuticals stock traded down $0.64 on Wednesday, hitting $13.55. 872,304 shares of the company were exchanged, compared to its average volume of 739,922. The stock has a market capitalization of $934.00 million, a price-to-earnings ratio of -5.06 and a beta of 1.93. The company has a 50-day moving average price of $10.97 and a 200 day moving average price of $8.21. Eyepoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $14.42.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $6.82 million. Research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.